The Lombardi Comprehensive Cancer Center (Lombardi) leadership consists of Dr. Louis Weiner, Lombardi Director;Dr. Peter Shields, Lombardi Deputy Director;Dr. V. Craig Jordan, Scientific Director;Mr. Michael Vander Hoek, Associate Director for Administration and Planning;Dr. Jeanne Mandelblatt, Associate Director for Population Sciences;Dr. John Marshall, Associate Director for Clinical Research;Dr. Anton Wellstein, Associate Director for Basic Science Research;Dr. Lucile Adams-Campbell, Associate Director for Minority Health and Health Disparities Research;Dr. Stephen Byers, Associate Director for Shared Resources;Dr. Anna Riegel, Associate Director for Education. Dr. Weiner assumed his responsibilities as Lombardi's Director, and Chair of the Department of Oncology at Georgetown University Medical Center (GUMC) on January 1, 2008. He is an internationally recognized authority on monoclonal antibody engineering and therapy. As Lombardi Director, Dr. Weiner Is responsible for organizing and coordinating the activities of the six research programs of the Cancer Center Support Grant (CCSG), 12 shared resources, and all other activities of Lombardi. Dr. Shields Is an expert on gene-environment interactions in cancer risk, and as Deputy Director, Is responsible for operational oversight of Lombardi activities, working in concert with Mr. Vander Hoek, who oversees Administration and Planning. Dr. Jordan, who joins Lombardi on July 1, 2009, Is widely known for his seminal work with tamoxifen and for development of the SERM hypothesis;was recently elected to the National Academy of Sciences. As Scientific Director, he will be responsible for overseeing Lombardi's scientific portfolio, enhancing transdisciplinary research, and overseeing the disbursement of pilot funds. The Associate Directors provide oversight of Lombardi's programs, shared resources, education and administration/planning, with an emphasis on fostering transdisciplinary interactions. Dr. Marshall is an internationally recognized gastrointestinal cancer clinical researcher, who provides oversight of Lombardi's clinical and clinical research operations, and oversees the two Lombardi clinical programs. Dr. Wellstein oversees the two basic science programs, and Dr. Mandelblatt oversees the two population science programs. Dr. Adams-Campbell Is an epidemiologist and recently elected member of the Institute of Medicine who will coordinate and extend Lombardi's efforts to address disparities across Its research portfolio. Dr. Byers is an accomplished molecular biologist who oversees all aspects of Lombardi's shared resources. Dr. Riegel coordinates Lombardi's graduate programs. Drs. Weiner, Shields effort, Jordan, Marshall and Mr. Vander Hoek comprise the Senior Operational Leadership Team (SOLT), which meets weekly. SOLT members also attend monthly Associate Director meetings and Program Leader meetings. This leadership team is ideally structured to achieve Lombardi's mission.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Georgetown University
United States
Zip Code
Bae, Woo Kyun; Yoo, Kyung Hyun; Lee, Ji Shin et al. (2015) The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers. Mol Carcinog 54:1172-80
Adams, Inez; Christopher, Juleen; Williams, Karen Patricia et al. (2015) What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2. J Cancer Educ 30:344-52
Butrick, Morgan; Kelly, Scott; Peshkin, Beth N et al. (2015) Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. Genet Med 17:467-75
London, Laricca; Hurtado-de-Mendoza, Alejandra; Song, Minna et al. (2015) Motivators and barriers to Latinas' participation in clinical trials: the role of contextual factors. Contemp Clin Trials 40:74-80
Mays, Darren; Niaura, Raymond S; Evans, W Douglas et al. (2015) Cigarette packaging and health warnings: the impact of plain packaging and message framing on young smokers. Tob Control 24:e87-92
Zhi, Xiuling; Lin, Ling; Yang, Shaoxian et al. (2015) ?II-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin. Hepatology 61:598-612
Rush, Christina L; Darling, Margaret; Elliott, Maria Gloria et al. (2015) Engaging Latina cancer survivors, their caregivers, and community partners in a randomized controlled trial: Nueva Vida intervention. Qual Life Res 24:1107-18
Heckler, Mary Mazzotta; Riggins, Rebecca B (2015) ERR? splice variants differentially regulate cell cycle progression. Cell Cycle 14:31-45
Kim, B; Wang, S; Lee, J M et al. (2015) Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene 34:1083-93
Tong, Angie; Kelly, Scott; Nusbaum, Rachel et al. (2015) Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. Psychooncology 24:33-9

Showing the most recent 10 out of 544 publications